CERA

Science and Research

KESTREL: A Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema

The purpose of the study is to evaluate the efficacy and safety of Brolucizumab in treatment of patients with visual impairment due to diabetic macular oedema.

Overview

This is a two-year, phase III, randomised, double masked, comparator controlled study of the study drug, Brolucizumab, for patients with diabetic macular oedema.

There are three arms that patients are randomized into: 3mg Brolucizumab on an 8-weekly interval,  6mg Brolucizumab on an 8-weekly interval, Aflibercept (Eylea) on an 8-weekly interval.

The purpose of the study is to evaluate the efficacy and safety of Brolucizumab in treatment of patients with visual impairment due to diabetic macular oedema.

  • Principal Investigator
Associate Professor Sanj Wickremasinghe

Learn more

View this study at ClinicalTrials.gov

This international database listing provides more detailed information about this study.